Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

DoJ Claims J&J Paid Kickbacks To Pharmacy To Boost Risperdal Use In Nursing Homes

This article was originally published in The Pink Sheet Daily

Executive Summary

The complaint says J&J paid Omnicare rebates to intervene in physician prescribing and sought to keep "best prices" down by substituting rebate payments for the purchase of Omnicare data.

You may also be interested in...



Medco Health Solutions Faces Second DoJ Probe In Five Years; Latest Involves AstraZeneca

Medco Health Solutions and AstraZeneca have received subpoenas from the DoJ for information involving arrangements pertaining to four AstraZeneca drugs.

Medco Health Solutions Faces Second DoJ Probe In Five Years; Latest Involves AstraZeneca

Medco Health Solutions and AstraZeneca have received subpoenas from the DoJ for information involving arrangements pertaining to four AstraZeneca drugs.

AstraZeneca's Seroquel Settlement With DoJ Is Fourth Targeting Antipsychotic Off-Label Promotion; Firm Avoids Criminal Charges

AstraZeneca's level of cooperation with the Department of Justice's investigation into allegations of off-label promotion for its antipsychotic Seroquel (quetiapine) may have helped shape the final $520 million civil settlement

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS070113

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel